Intrinsic Value Partners, LLC Ironwood Pharmaceuticals Inc Transaction History

Intrinsic Value Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	SELL	$5.58 - $8.61 $12,889 - $19,889	-2,310 Reduced 4.84%	45,435 $296,000
Q1 2024 Apr 22, 2024	SELL	$8.32 - $15.45 $14,227 - $26,419	-1,710 Reduced 3.46%	47,745 $415,000
Q4 2023 Feb 07, 2024	SELL	$8.79 - $11.51 $7,910 - $10,359	-900 Reduced 1.79%	49,455 $565,000
Q3 2023 Oct 17, 2023	SELL	$8.25 - $11.35 $412 - $567	-50 Reduced 0.1%	50,355 $484,000
Q2 2023 Aug 02, 2023	SELL	$10.1 - $11.6 $12,120 - $13,920	-1,200 Reduced 2.33%	50,405 $536,000
Q1 2023 Apr 18, 2023	SELL	$10.37 - $12.56 $3,110 - $3,768	-300 Reduced 0.58%	51,605 $542,000
Q4 2022 Jan 12, 2023	SELL	$9.9 - $12.43 $18,810 - $23,617	-1,900 Reduced 3.53%	51,905 $643,000
Q3 2022 Oct 13, 2022	SELL	$10.14 - $12.38 $3,042 - $3,714	-300 Reduced 0.55%	53,805 $557,000
Q2 2022 Jul 18, 2022	SELL	$11.05 - $12.72 $4,132 - $4,757	-374 Reduced 0.69%	54,105 $624,000
Q1 2022 Apr 28, 2022	SELL	$10.61 - $12.88 $6,132 - $7,444	-578 Reduced 1.05%	54,479 $685,000
Q4 2021 Feb 10, 2022	BUY	$10.86 - $13.95 $597,919 - $768,045	55,057 New	55,057 $642,000

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $541M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Intrinsic Value Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Intrinsic Value Partners, LLC with notifications on news.